POSC157 Treatment of Moderate-to-Severe Active Psoriatic Arthritis: Cost-Effectiveness Analysis and Budget Impact Analysis of Biologics and Targeted Therapies Approved in the Russian Federation
Jan 1, 2022, 00:00 AM
10.1016/j.jval.2021.11.559
https://www.valueinhealthjournal.com/article/S1098-3015(21)02354-8/fulltext
Section Title :
Section Order :
10094
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02354-8&doi=10.1016/j.jval.2021.11.559